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suggested so that disease progression, deformites, 
and other extraarticular manifestations can be 
prevented. American College of Rheumatology 
(ACR) recommendation urges all clinicians to use 
‘treat-to-target’ strategy in treating Rheumatoid 
Arthritis (RA). It means that the treatments given 
must targetting remission or low disease activity.1 
This goal can only be achieved if clinicans evaluate 
patients’ disease activity periodically, so they can 
adjust the dosage or giving combination disease 
modifying antirheumatic drugs (DMARD). 
Clinical disease activity index (CDAI), as one 
of many disease activity measures endorsed by 
ACR, has superiority among others in terms of 
its practical and efficiency aspect. CDAI combine 
both physician’s and patient’s assesement while 
omit requirement of laboratory test (c-reactive 
protein/CRP), it is beneficial from the physicians 
standpoint who provide care for RA patients in 
limited laboratory resources or in limited healthcare 
budget setting. Another advantage of using CDAI 
is that its time-efficiency. CDAI can be calculated 
onsite and does not  need to wait laboratory test to 
come out. 
However, previous studies revealed that 
CDAI outcome has good correlation compared 
to other measures that incorporate acute phase 
reactant component.2-11 Yet those studies cannot be 
instantly applied to Indonesian patients who might 
have some comorbidities. Indonesian RA patients 
have distinct clinical charateristics, includes: (1) 
Most Indonesian RA patients come with one or 
more comorbidities, mainly infectious disease; 
(2) Indonesian RA patients has distinct genetic 
predisposition compared to caucassian RA patients; 
this causes a different clinical manifestation and 
degree of disease progression in Indonesian RA 
patients. 12-19
Until today, there has not been any studies that 
analyze how is the correlation of CDAI outcome 
compared to other scoring indexes in Indonesian 
RA patients. This study aimed to answer the 
question. 
Abstract
Background:Clinical Disease Activity Index (CDAI) 
stands out amongst other methods in measuring disease 
activity of rheumatoid arthritis (RA) patient. CDAI is 
considered to be more practical and cost-effective 
in daily practice because it requires no laboratory 
examination. Previous studies conducted overseas 
revealed that CDAI has good correlation compared to 
other scoring index in measuring RA disease activity. 
However, those studies only included pure RA patients 
without any comorbidity diseases. Indonesian RA 
patients have distinct clinical profile, in terms of 
comorbidity conditions, and genetic predisposition which 
affect the fenotype of the disease. 
Objectives: Analyze correlation between CDAI 
compared to Disease Activity Score 28 CRP (DAS28-
CRP) in measuring RA disease activity of RA patients in 
Indonesia. 
Methods: We conducted a cross sectional study to 
RA patients who visited rheumatology clinic at Cipto 
Mangunkusumo general hospital from April to May 
2016. Data collected included history of illness, physical 
examination, and recent laboratory results. All data were 
documented in reseach’s form. Both CDAI and DAS28-
CRP were measured in each patient by two observers. 
Correlation analysis between two numeric datas from 
CDAI and DAS28-CRP were measured with Spearman’s 
Rho. Overall performance was analyzed as additional 
results using R2 index. 
Result: A total of 119 subjects were included in this 
study. All subjects were RA patients with comorbidities 
and were  representing quite numbers of Indonesian 
races characteristic profile. Spearman’s Rho = 0,918 
and R2 index =0,831 (83,1%).
Conclusion: There is positive correlation result between 
outcome of CDAI and outcome of DAS28-CRP in 
assesing disease activity of Indonesian RA patients.
Key Word: rheumatoid arthritis, Indonesia, correlation, 
Clinical Disease Activity Index.
Backgrounds
Rheumatoid arthitis is a chronic debilitating disease. 
A periodic assessment of disease activity is strongly 
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METHODS
This is a cross-sectional study which was conducted to 
RA patients who visited rheumatology clinic at Cipto 
Mangunkusumo National Referral Hospital on April to May 
2016.
Sampling were obtained in consecutive manner. Inclusion 
criteria for this study were patients who have been well-
established diagnosis as RA according to 2010 ACR/EULAR 
Criteria and agreed to be involved in this study. All subjects 
were comprehensively examined, with history taking, 
physical examination, and laboroatory test documentation. 
CDAI and DAS28-CRP were measured to all subjects. CDAI 
was used as the main test, while DAS28-CRP was used as the 
comparator. Each measurements were conducted in blind way 
by two trained-physicians, the researcher and a rheumatology 
consultant.
Datas were served as numerics, and analyzed using SPSS 
23.0. Interclass coefficient correlation (ICC) were analyzed 
using Cronbach’s alpha. Correlation analysis was measured 
by Spearman’s Rho with its range varies from -1 and +1. A 
positive correlation coefficient indicates a positive relation 
between two variables (CDAI and DAS28-CRP). A negative 
coefficient indicates negative relationship. A zero  coefficient 
indicates no relationship between two variables. Overall 
performance was measured as additional results using R2 
index, which depicts predictor aspect of one variable outcome 
to another. R2 >64% suggests a very good prediction model.20-25
Results
This study recruited 119 subjects. All subjects were 
RA patients with at least two comorbidities. The four most 
frequent comorbidities found were dylipidemia 46.2%, 
obesity 37%, hypertension 36.1% and infection 26.1%. 
Eighty-three (69.7%) commorbidities were classified as 
“other comorbidities” due to the small number of various 
comorbidities. Those comorbidities were osteoarthritis, 
cervical-lumbal spondyloarthrosis, rotator-cuff tendinitis, 
plantar fasciitis, hernia nucleus pulposus, avascular 
necrosis of hip, carpal tunnel syndrome, asthma, chronic 
pulmonary obstructive disease, inflammatory bowel disease, 
gastritis, esophagitis, melena, hematoschezia, dyspepsia, 
ureterolithiasis, cataract, congestive heart disease, stabil 
angina, chronic vein insuficiency, dan pregnancy 
All subjects represent all range of disease activity from 
remission to high disease activity. Most subjects fit into range 
of moderate disease activity, 42% in CDAI and 34.5% in 
DAS28-CRP. 68.1% subjects were using single DMARD and 
1.7% subjects were using biologic agents (Tocilizumab).
Clinical and demographic characteristics of subjects were 
depicted in Table 1, Subject disease activity characteristics 
were depicted in Table 2.
 
Table 1. Clinical and Demographic Characteristics of Subjects
Characteristics Result (N=119)
Demography
       Age, (year)
Female, N (%)
Positive Rheumatoid Factor, N(%)
Duration of RA, (months)
Low education level, N (%)
Domicile outside Jakarta, N (%)
Ethnic
    Java, N (%)
    Sunda, N (%)
    Batak, N (%)
    Betawi, N (%)
    Minang, N (%)
    Chinese, N (%)
    Palembang, N (%)
    Bangka, N (%)
    Ambon, N (%)
    Others, N (%)
Aspect of Therapeutic
Single DMARD, N (%)
Combined DMARD, N (%)
Methotrexate, N (%)
Sulfasalazin, N (%)
Chloroquin, N (%)
Leflunomide, N (%)
Steroid , N (%)
Biologic agents, N (%)
Adjuvant analgetics, N (%)
Aspect of Comorbidity
54 (21-75)**
107 (89,9%)
49 (41,2%)
30 (2-162)**
36 (30,2%)
46 (38,7%)
34 (28,5%)
21(17,6%)
18 (15,1%)
14 (11,7%)
13 (10,9%)
7 (5,8%)
3 (2,5%)
2 (1,6%)
2 (1,6%)
5 (4,2%)
81 (68,1%)
34 (28,6%)
100 (84%)
43 (36,1%)
6 (5%)
5 (4,2%)
55 (46,2%)
2 (1,7%)
29 (24,4%)
Dyslipidemia, N (%)
Obesity, N (%)
Hypertension, N (%)
Diabetes, N (%)
Coronary artery disease, N (%)
Peripheral artery disease, N (%)
Neoplasm, N (%)
Lung Tuberculosis, N (%)
Pneumonia, N (%)
Other infections, N (%)
Other Autoimune disease, N (%)
Chronic liver disease, N (%)
CKD or AKI, N (%)
       Other comorbidities , N (%)
55 (46.2%)
44 (37%)
43 (36,1%)
13 (10,9%)
7 (5,9%)
3 (2,5%)
18 (15,1%)
4 (3,4%)
3 (2,5%)
31 (26,1%)
2 (1,7%)
13 (10,9%)
4 (3,4%)
83 (69,7%)
*: normal data distribution (mean ±SD); **: not normal data distribution 
(median, min-max); Low education level: less than high-school level
Table 2. Disease Activity Evaluation
Disease Activity Results
Clinical
Sum of tender joints 
Sum of swollen joints 
Laboratorium
C-reactive protein (mg/dL)
Erythorcyte sedimentation mate (mm/hour)
Global Assesment
Patient’s Global Assesement DAS28-CRP (0-100)
Patient’s Global Assesement CDAI  (0-10 mm)
Physician’s Global Assesement CDAI (0-10 mm) 
Positive Deformity, N (%)
2 (0-27)**
0 (0-8)**
3,1 (0,1-89,9)**
43 (4-108)**
40 (0-80)**
4 (0-8)**
4 (0-8)**
38 (31.9%)
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CDAI Score (median,min-max)
DAS28CRP Score (median,min-max)
CDAI Disease Activity Classification
Remission, N (%)
                 Low disease activity, N (%)
Moderate disease activity, N (%)
High disease activity, N (%) 
DAS 28-CRP Disease Activity Classification
Remission, N (%)
Low disease activity, N (%)
Moderate disease activity, N (%)
High disease activity, N (%)
10 (3-45)**
2,9 (1,15-6,15)**
 12 (10,1%)
   42 (35,3%)
50 (42%)
15 (12,6)
36 (30,3%)
36 (30,3%)
41 (34,5%)
6 (5%)
*: normal data distribution (mean ±SD); **: not normal data distribution 
(median, min-max)
Interclass coefficient correlation revealed Cronbach’s 
alpha were 0,999 dan 0,996 (p<0,01). Spearman’s Rho =0,918 
(p < 0.01); R2 index= 83,1% ( p < 0.01); Adjusted R2= 82.9% 
(p < 0.01)  Correlation plot were depicted in Figure 1.
Figure 1. Correlation Plot of CDAI and DAS28-CRP
DISCUSSION
Clinical disease activity index (CDAI) is a practical approach 
to asses disease activity which is not requiring any laboratory 
test. CDAI only incorporates aspects from both  physician’s 
and patient’s assesement standpoint. This study assesed how 
well the correlation disease activity assesed by CDAI to other 
well-established disease activity scoring index, DAS28-CRP. 
Previous studies which conducted in RA patients without 
any comorbidities revealed that CDAI and DAS28 has good 
correlation. We suggested that in RA patients with comobid 
conditions, the correlation of CDAI and DAS-28 CRP would 
not work so well since the comobidities may increase CRP 
values. The increase of CRP values can lead the discrepancy 
between CDAI and DAS28-CRP, since CDAI does not include 
CRP value, while DAS28 does. 
 The rise of CRP does not solely happen due to the increase 
RA disease activity. Comorbidities, like infections, neoplasm, 
metabolic degenerative diseases, and other autoimmune 
diseases,  may as well cause the rise of CRP as RA conditions. 
In daily practice, we rarely encounter patient with single 
disease entity. We used to treat RA patients with multiple 
comorbidities. Using CRP as a factor calculated in RA disease 
activity scoring index might produce bias results, because 
the rise of CRP is also happened due to the comorbidities 
condition, with or without any increase in RA disease activity.
In this study we found a positive correlation of CDAI 
outcomes with DAS28-CRP outcomes. Spearman correlation 
analysis showed Rho=0,918 (p<0,01). It is revaled that, 
in assesing RA patients with comorbidites, both CDAI and 
DAS28-CRP still has good concordance results. 
In addition, we also analyzed overall performance of 
CDAI compared to DAS28-CRP, using  R2 index analysis. 
In its process, R2 index analysis is related to linear regression 
analysis, a technique of fitting lines to data and checking how 
well the line describes the data. Linear regression examines 
the relationship between a change in the value of one variabel 
(predicted) and the corresponding change in the outcome 
variable (observed). Linear regression is depicted in two 
axis (X and Y) curve, and relationship between observed 
and predicted is summarized as a diagonal line. Conclusion 
drawn from linear regression analysis is stronger and deeper 
than correlation analysis. While correlation analysis measure 
only the strength and direction of association between two 
variables. We cannot interpret further whether the association 
is predictive or causative, since correlation analysis only 
shows how well two variables relate to each other. On the other 
hand, linear regression analysis reflects not only relationship 
between two varibles but it can also explain predictive and 
causative aspect between two variables, as the regression line 
is determined as the best way to predict the outcome of Y from 
the X. So at the end, conclusions drawn from linear regression 
analysis are more ready-to-apply in daily clinical practice, 
than conclusions drawn from correlation analysis. 22-26
The R2 index implies how well CDAI outcome could reflect 
DAS28-CRP outcome. We use DAS28-CRP as comparator 
because we consider DAS28-CRP as the most comprehensive 
score, which combines aspect of evaluation from physician’s, 
patient’s and laboratory standpoint. Moreover, DAS28-
CRP is one of the oldest and earliest score developed by 
EULAR.27-28  If we looked back in 1990 when EULAR first 
described DAS as a measure to asses disease activity, using 
extensive joints count. Along with its development, EULAR 
had been frequently remodifying DAS into DAS 4 variables, 
then DAS 3 variables, until it becomes DAS28-CRP as we 
know today.27-29   Revision were subjected to the development 
of DAS score along with invention and development of new 
scientific proofs. A score that frequently revised/remodified 
can be considered comprehensive enough, so that is way we 
use DAS28-CRP as gold standard. 
Correlation/calibration plot (Figure 1) shows a diagonal 
line which is a best-fit model that can predict outcome of Y 
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axis (DAS28-CRP) from outcome of X axis  (CDAI). In other 
words, a regression line is also called the line of best fit because 
it is the line that best represents the pattern of the relationship 
between the dependent variable and the independent variable. 
The formula of best-fit line can be determined by equation 
of  y=a+b(x), a represent the point where the regression line 
crosses the Y axis, called the intercept (the value of Y when 
X is zero) , while b represent the slope of the regression line, 
indicating how much the Y value changes when there is a one-
unit change in the value of X. It indicates the strength of the 
relationship between X and Y (the regression coefficient). 
In the statistic analysis of SPSS 23, the we can instantly get 
the number for a and b. In this study, a = 1,517 and b=0,131, so 
by using equation of Y=a+b(X), predictor equation of CDAI 
is Y= 1,51 + 0,13(X). 22-25   
Once we identify the regression line, it is important to 
assess how well it predicts an outcome from the basis of a 
known variable. (outcome of DAS28-CRP from the basis of 
CDAI). From the scatterplot (Figure 1) we can see dispersion 
of the points will affect how accurate the estimate is likely to 
be. With this predictive model, we calculate a R2 (coefficient 
of determination) to measure how much is the variance of 
DAS28-CRP explained by the variance of CDAI. The R2 index 
may vary from 0 to 1. The closer R2 to 1, means the better 
prediction model is. While R2= zero, that means none of the 
variance is shared between the two variables, both variables 
are completely unrelated. 22-25   This study reveals  that R2 
index index of CDAI is  very good (83.1%), since R2 index 
>64% is considered very good.
Aside from R2, there is also adjusted R2 . Adjusted R2  is the 
value of R2 when the sample size is small, because an estimate 
of R2 obtained when the sample size is small tends to be higher 
than the actual R2 in the population. The adjusted R2 is reported 
only  when it substantially differs from R2 . In this study,  the 
adjusted R2 = 0,829 (82,9%) . Since the difference between 
R2 and adjusted R2 = 0,829 very small (0.002). Therefore, we 
can report the R2 . Given the fact that there is small difference 
between R2 and adjusted R2, also show that the number of 
samples recruited in this study is adequate. 20,22-25.
This study revealed that CDAI has good performance in 
assesing disease activity, even without incorporating CRP 
value. This finding is in line with the conclusion from study 
conducted by Aletaha, et al,3 which said CRP contribute 
small proportion (15%) to overall DAS28-CRP composition. 
The equation of DAS28-CRP is as follow: 0,56√tender joint 
counts + 0,28 √swollen joint counts + 0.36 ln (CRP+1) 
+ 0,014(patient’s global assesement)) +0,96.  While the 
equation of CDAI is as follow: tender joint counts + swollen 
joint counts+ patient’s global assesement+ physician’s 
global assesement. From that equation, we can see that CRP 
component in DAS28-CRP is purposefully reducted by log 
linear calculation. This has implication in reducing CRP 
contribution to  final result of DAS28-CRP. On the other hand, 
CDAI score has no reduction component for all components 
calculated to final result. This explain why the omission of 
CRP componenet in CDAI, do not interfere its performance in 
assesing disease activity. 
We believe that the  reduction of  CRP contribution 
in overall DAS28-CRP calculation, has a deep scientific 
and logical reasoning. In vitro pathogenesis of RA reveals 
that progression of  joint erosion and joint deformity is 
happened because of the work of spesific cells and cytokines 
cascades, named Matrix Metalloproteinase (MMP)-1, MMP-
3, Epidermal Growth Factor, VCAM, VEGF, YKL-40, 
Lymphocyte T, IgM Rheumatoid Factor, Antibodi Anti-Cyclic 
Citrullinated Protein (AntiCCP), Tumor Necrosis Factor 
(TNF), IL-6, IL-8, IL-17, RANKL. While CRP is not a spesific 
acute phase reactant, it is produced by liver and adipocyte, and 
does not play significant roles in the process of joint erosions, 
joint destructions, and deformities. Secretion of CRP, as part 
of innate immunity mechanism, happens generally, not only 
because of RA activity, but also due to other conditions, such 
as infections, metabolic diseases, neoplasm, degenerative 
diseases, and other inflammatory conditions. 30,31 
CDAI has good performance in assesing disease activity in 
RA patients with or without any comorbidities. Using CDAI, 
clinicians can perform periodical disease activity evaluation 
without performing or waiting for any laboratory test (CRP). 
It can be implicated that CDAI is more time and cost-efficient 
for clinicans in making theraupetical decision. Clinicians can 
easily calculate the CDAI score because the formulation is 
more simple than the formulation of DAS28-CRP. With those 
reasons, CDAI are allowed to be delivered to all RA patients, 
both in rural and urban area, or in limited and advanced 
healthcare resources. 
CONCLUSION
Clinical disease activity index has good correlation outcome 
compared with DAS28-CRP in measuring disease activity of 
Indonesian RA patients. 
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